First-of-its-Kind cell therapy trial targets Hard-to-Treat autoimmune illnesses
NCT ID NCT07167537
Summary
This early-stage study is testing the safety of a new cell therapy called OL-CD19-GDT for adults with severe autoimmune diseases that haven't responded to other treatments. The therapy involves modifying a patient's own immune cells to potentially reset the immune system and reduce disease activity. Researchers will closely monitor 44 participants for side effects and early signs of improvement over a year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS (SSC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing GoBroad Hospital
RECRUITINGBeijing, 102206, China
Conditions
Explore the condition pages connected to this study.